Investor Webinar - Q4 FY26 Investor Presentation Deck
Released
Released
Announcement PDF
0
Q4 FY26 Investor Presentation
ASX:RCE | FSE:R9Q
July 2026
Disclaimer
DISCLAIMER
This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does
not purport to contain all the information that a prospective investor may require in connection
with any
potential investment in the Company. You should not treat the contents of this presentation,
or any information provided in connection with it, as financial advice, financial product advice
or advice relating to legal, taxation or investment matters.
No representation or warranty (whether express or implied) is made by the Company or any
of its officers, advisers, agents or employees as to the accuracy, completeness or
reasonableness of the information, statements, opinions or matters (express or implied)
arising out of, contained in or derived from this presentation or provided in connection with it,
or any omission from this presentation, nor as to the attainability of any estimates, forecasts
or projections set out in this presentation.
This presentation is provided expressly on the basis that you will carry out your own
independent inquiries into the matters contained in the presentation and make your own
independent decisions about the affairs, financial position or prospects of the Company. The
Company reserves the right to update, amend or supplement the information at any time in its
absolute discretion (without incurring any obligation to do so).
Neither the Company, nor its related bodies corporate, officers, their advisers, agents and
employees accept any responsibility or liability to you or to any other person or entity arising
out of this presentation including pursuant to the general law (whether for negligence, under
statute or otherwise), or under the Australian Securities and Investments Commission Act
2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding
provision of any Australian state or territory legislation (or the law of any similar legislation in
any other jurisdiction), or similar provision under any applicable law. Any such responsibility or
liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.
Nothing in this material should be construed as either an offer to sell or a solicitation of an
offer to buy or sell securities. It does not include all available information and should not be
used in isolation as a basis to invest in the Company.
1
FUTURE MATTERS
This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of
the Company.
Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are
based on certain assumptions, which may not be met or on which views may differ and may be affected by
known and unknown risks. The performance and operations of the Company may be influenced by a number of
factors, many of which are outside the control of the Company. No representation or warranty, express or
implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any
intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will
be achieved.
Given the risks and uncertainties that may cause the Company’s actual future results, performance or
achievements to be materially different from those expected, planned or intended, recipients should not place
undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not
warrant or represent that the actual results, performance or achievements will be as expected, planned or
intended.
US DISCLOSURE
This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any
securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S
under the US Securities Act of 1933 (“Securities Act”). The Company’s shares have not been, and will not be,
registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States,
and may not be offered or sold in the United States or to any US person without being so registered or
pursuant to an exemption from registration including an exemption for qualified institutional buyers.
Company
Overview
Recce Pharmaceuticals – Company Overview
RECCE® 327 granted Qualified Infectious Disease Product (QIDP)
Designation by U.S. Food and Drug Administration giving 10 years
market exclusivity plus fast-track approval.
RECCE® 327 added to World Health Organization’s List
of Antibacterial Products in Clinical Development.
3
Recce Pharmaceuticals is a leading, Australian anti-infective company approaching near term commercialisation milestones
Products address the global healthcare crisis of antibiotic resistance: working
faster than traditional antibiotics and against multidrug resistant bacteria
Patient dosing has commenced for Phase 3 clinical trial in Indonesia of lead
asset RECCE® 327 Gel for the treatment of Diabetic Foot Infections – interim data
readout expected Q3 CY2026 and commercialisation in 2027
Recce has signed a non-binding term sheet with a leading Middle Eastern
pharmaceutical company for a 10-Year exclusive multi-country licensing
agreement
Multiple clinical indications and formulations addressing unmet medical needs
Agreements with US Defense Burn Research Program and US Army Medical
Research Institute of Infectious Diseases further support Recce's product
potential
Large Addressable Market
4
The global diabetic foot infection (DFI) market represents a substantial burden on global healthcare systems
US$5.8B
Est. global DFI
treatment
market1
Source: (1) Grand View Research, Diabetic Foot Ulcer Treatment Market Size, 2025 (2) Grand View Research, Anti-Infective Agents Market Size, 2023 (3) Diabetes Atlas, International Diabetes Federation (IDF) and Prof EM Yunir, Faculty of
Medicines, University of Indonesia. (4) https://diabetesatlas.org/data-by-location/region/middle-east-and-north-africa/ (5) https://idf.org/about-diabetes/diabetes-facts-figures/ (6) The current burden of diabetic foot disease – PMC (7)
https://doi.org/10.1016/j.heliyon.2024.e41263
INDONESIA MENA GLOBAL
>20 million
adults in Indonesia with
diabetes3
>84 million
adults in MENA region
with diabetes4
>589 million
adults globally with
diabetes5
Est. global market
opportunities in the
anti-infectives
market2
• For adults with diabetes, approximately one in three adults
will develop a diabetic foot ulcer in their lifetime6
• In Indonesia, DFIs are severe in 67.1% of hospitalised cases
and result in amputation in 46.9% of patients7
US$135.4B
5
Key highlights for the quarter ended 30 June 2026
A transformational quarter delivering regulatory, clinical and commercial milestones that further de-risk Recce's global development strategy
Clinical Update
Australian DFI study
advanced to a pivotal Phase
3 registrational trial.
Regulatory Progress
Indonesian BPOM
completed a
comprehensive inspection
with no findings or
required changes.
Commercialisation
Signed non-binding
licensing term sheet
with a leading Middle
Eastern pharmaceutical
company.
Patient eligibility expanded to
include Moderate DFI,
significantly increasing
recruitment potential.
Trial design strengthened
through additional ulcer-level
endpoint analysis.
Proposed agreement
includes upfront
payments, milestones,
product revenue share
and royalties.
Commercial negotiations
progressing toward a
definitive agreement.
Australian HREC approved
protocol amendments
supporting an accelerated
global registration strategy.
Two registrational Phase 3
studies now operating
concurrently.
Global Expansion
Dual Phase 3 strategy now
supports future
registrations across
Australia, Indonesia,
ASEAN, MENA and the
United States.
MENA licensing opportunity
covers 12 countries with
access to one of the world's
highest diabetes burden
regions.
Recce continues building a
global commercial platform.
Registrational Phase 3 Clinical Trial - Australia
6
Randomised, Active Comparator Study of R327 Topical Gel for the Treatment of Diabetic Foot Infections
Study Overview
Primary Endpoint: Assess the clinical response of the DFI according to the Lipsky Scale.
Secondary Endpoints: DFI total wound score and safety of R327G.
Endpoints
TGA and US FDA regulatory standards
R327 Topical
DFI
Australia/USA
2026 2027
Timeline
Additional Registrational Clinical Trials and
Data for AUS/US Approval
R327G
Registered in
Australia/US
2028
Expanded Patient Population
Protocol amendment adds moderate DFI. Mild and Moderate DFI
together represent 80% of DFI presentations1.
Phase 3
Interim
Data Readout
1 Lavery LA, Armstrong DG, Murdoch DP, Peters EJG, Lipsky BA. Validation of the Infectious Diseases Society of America's diabetic foot infection classification
system. Clinical Infectious Diseases. 2007;44(4):562–565.
• Indonesian National Agency of Drug and Food Control (Badan POM) has
not requested any changes to the ongoing clinical trial
– The inspection was completed with no findings noted that prevent the study
from continuing.
– The outcome reflects the high quality of the Recce’s clinical operations in
Indonesia and adherence to regulatory requirements.
7
Indonesian Minister of Health, Mr. Budi Sadikin:
“The global health challenge of antimicrobial
resistance is a pressing issue on the world stage.
Indonesia welcomes collaborative initiatives and
supports efforts to combat antimicrobial resistance,
including the development of innovative
therapeutics for infectious diseases.”
• Comprehensive regulatory inspection successfully completed for Phase 3
clinical trial site for the treatment of DFIs
– Inspection formed part of BPOM’s standard regulatory oversight of clinical
studies and included a comprehensive review of trial conduct, site processes,
data integrity, and compliance with applicable Good Clinical Practice (GCP)
standards.
• Phase 3 clinical trial patient dosing continues across five sites with interim
data analysis to be conducted at 155 patients completed
– BPOM inspection represents a critical de-risking milestone for Recce’s
registrational Phase 3 clinical trial in Indonesia and supports the pathway
toward regulatory approval and commercialisation in Indonesia followed by
other ASEAN countries.
Routine Regulatory Inspection of Indonesian Sites
recce.com.au
Program Pipeline* driven by 1st approval in Diabetic Foot Infections
2026 2027 2028 2029 2030
R327 Topical
R327 Topical
R327 I.V. Program
R327 Inhaled – Lung Infections
Civil & Dept of War Programs
Phase 3 Interim Data Readout
- 155 patients
Hospital-Acquired Pneumonia (HAP)
Ventilator Associated Pneumonia (VAP)
DFI/ABSSSI AUSTRALIA/USA
Diabetic Foot Ulcer Infection GEL
INDONESIA/ASEAN
Burn Wound Infections USA
Mechanism of Action (MoA)
Peer Reviewed Publication
MoA paper
published
Phase I/II Trials of R327
Nebuliser
Preclinical Trials of R327
Nebuliser
Registrational Trials of
R327 Nebuliser
Potential Phase II Trials of R327 IV
Preclinical Trials of R327G with
Department of War (DoW)
Additional Registrational Clinical
Trials and Data for AUS/US
Approval
Indo trial data
used for global
registration strategy
R327G
Registered in
Australia/US
File NDA
Phase I Complete,
safe and well tolerated
*The information and forecasts presented reflect management’s current expectations as at the date of this presentation. These statements involve assumptions, including the availability of appropriate
funding, and are subject to known and unknown risks and uncertainties. Actual outcomes may differ from those expressed or implied and the Company reserves the right to revise its plans, projections,
and strategic priorities as circumstances change.
Registrational Trials of R327G
For Burn Wounds
Phase 3 Interim
Data Readout
Positive Indonesian Phase 3 Clinical Trial data readouts,
together with subsequent regulatory approval would
support commencement of commercialisation activities
in Indonesia, ASEAN and MENA
R327G
Registered
in Indonesia
R327G
Registered
in ASEAN
9
Recce Global Growth Strategy
Indonesian regulatory approval serves as a foundation for a cascading global approval strategy across multiple regions
Expansion into
ASEAN & MENA
Expansion across
Australia/NZ
Expansion to
USA/DoD
Global Approvals
New Products and
New Indications
Gel IV Aerosol
DFI Gel
ABSSSI Gel
Burn Gel
IV cUTI
IV Sepsis
IV Single Dose UTI
Aerosol HAP / VAP
Aerosol non-TB
Mycobacteria
Intranasal Sinusitis
Unlocks
MENA Diabetes Market
• The MENA region has a diabetes prevalence of 17.6% with over 84 million people living with diabetes – in Saudi Arabia,
23.1% of the adult population have been diagnosed with diabetes
• The non-binding Term Sheet coverage is across the KSA, GCC countries (UAE, Kuwait, Oman, Bahrain, Qatar), Iraq,
Egypt, Algeria and Morocco
Validation of
Premium Pricing
• Non-binding Term Sheet stipulates a proposed selling price of USD $1,500 per treatment or a price mutually agreed
with the KSA regulatory authority
• Recce expected to receive 30% of the Net Selling Price with an additional 6% annual royalty on net sales >USD$50
million/year
Data Harmonisation
from Indonesia
• Successful data read outs in Indonesia together with subsequent regulatory approval would support commercialisation in
Indonesia and may support similar regulatory approval and commercialisation in other ASEAN markets.
• Pending positive Phase 3 clinical trial results from the ongoing Indonesian trial, no additional clinical trials are expected to
be required to support a marketing authorisation application in Saudi Arabia
Commercial Partnership
with Leading Company
• The partner is recognised as one of the leading pharmaceutical companies in the MENA region
• With a strong sales portfolio of products across dermatology, endocrinology and infectious diseases and established
market access throughout the region, the partner is well positioned to accelerate the adoption and distribution of R327G
Middle Eastern Pharmaceutical Company Term Sheet
10
Recce has signed a non-binding term sheet with a leading Middle Eastern Pharmaceutical Company for a 10-year exclusive
multi-country licensing agreement for the licensing of R327G through the MENA region
Non-binding term sheet is a positive step towards the potential commercialisation of R327G across one of the world's
most significant diabetes markets
Term Sheet Highlights
Intellectual
Property &
Manufacturing
11
Robust Worldwide Intellectual Property Portfolio
12
Family 1 group relates to the Company’s Unique and
Highly Economical Manufacturing Process and use of the
Polymer in Treatment of Diseases.
Family 2 relates to the Method of Manufacture,
Administration and Application to Treat a Broad Range of
Common Human Infections.
Family 3 relates to a Method of Treatment of a Broad
Range of Viral Infections, particularly Parenteral Viral
Infection.
Family 4 relates to Process for Preparation of
Biologically Active Copolymer, other Patent Cooperation
Treaty countries pending/granted.
Recce’s patent portfolio contains over 40 patents and patent applications in the world’s major markets.
Filed
Patent
Family 1
Expiry
Patent
Family 2
Expiry
Patent
Family 3
Expiry
Patent
Family 4
Expiry
Australia ✓ 2028 ✓ 2037 ✓ 2037 ✓ 2041
USA ✓ 2029 ✓ 2037 ✓ 2037 Pending
Europe ✓ 2028 ✓ 2037 ✓ 2037 Pending
Germany ✓ 2028 ✓ 2037 ✓ 2037
Spain ✓ 2028 ✓ 2037 ✓ 2037
France ✓ 2029 ✓ 2037 ✓ 2037
UK ✓ 2028 ✓ 2037 ✓ 2037
Italy ✓ 2028 ✓ 2037 ✓ 2037
Sweden ✓ 2028 ✓ 2037 ✓ 2037
Japan ✓ 2028 ✓ 2037 ✓ 2037 ✓ 2041
China ✓ 2028 ✓ 2037 ✓ 2037 ✓ 2041
HK Pending 2028 Pending 2037 ✓ 2037 ✓ 2041
Israel ✓ 2041
Canada ✓ 2041
Brazil ✓ 2041
Vietnam ✓ 2041
Share Purchase Plan Now Open and Use of Funds
13
Under the SPP, Eligible Shareholders will have the opportunity to purchase Shares up to the value of $30,000 at an issue price of A$0.40 per Share, irrespective of the size of their shareholding in Recce, without incurring brokerage or
transaction costs.
Eligible Shareholders are registered holders of shares in the Company as at 7:00pm Australian Eastern Standard Time (AEST) on 25 June 2026 (Record Date) and whose registered address on the Company’s share register is in
Australia, New Zealand or in the United States (provided that such US shareholders are Accredited Investors).
Event Date
SPP Record Date 7:00pm (AEST), Thursday, 25 June 2026
SPP Offer Booklet made available to eligible
shareholders and SPP Offer open date Monday, 6 July 2026
Revised SPP offer closing date 5:00pm (AEST) Friday, 24 July 2026
Revised Last day to announce results of SPP Friday, 31 July 2026
Revised Allotment and issue of new shares under
the SPP Friday, 31 July 2026
Revised Commencement of trading of new shares
under the SPP Monday, 3 August 2026
General Meeting (GM) On or about Monday, 31 August 2026
Lodgement of Prospectus with ASIC and ASX in
relation to Attaching Options and Piggyback
Options
On or about Wednesday, 2 September 2026
Use of Funds and Available Liquidity
Funds raised under the Placement and SPP will be used for the following
activities:
• A$3.2 million – Strengthen the balance sheet for commercial licensing
with leading Middle Eastern Pharmaceutical Company including initiatives
to support the commercial agreement
• A$2.0 million – Clinical trials (significant, unmet medical needs) including:
– Completion of Phase 3 DFI Registrational Topical Clinical Trial in
Indonesia
– Phase 3 DFI Registrational Topical Clinical Trial in Australia (for US
FDA)
– Continuance of US Department of War Burn Wound Program
• A$2.0 million – Activities enabling Investigational New Drug application to
FDA & the Indonesia FDA (BPOM)
• A$0.8 million – General working capital (operational costs delivering
above) and Offer costs
recce.com.au
Company Financials
Capital Structure – July 2026
ASX & FSE Code RCE, R9Q
Share Price AUD $0.385
3-Month Average
Daily Volume
160.98k
Shares on Issue 289.18 million
Unlisted Options (Avg $1.087) 24.17 million
Market Capitalisation AUD $115.3 million
Top 20 Shareholders 57%
RCE Share Price and Volume Chart – 12 Months (price shown in AUD)
Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives
Volume Close $
*Includes proceeds from Capital Raise (before offer costs) and if debt component is drawn (subject to certain time limitations and the satisfaction of certain conditions)
14
The Company expects the receipt of further non-
dilutive funds and capital raise proceeds, which
extends Recce's pro-forma cash position of AUD
~$33.1 million* (previously $29.5 million).
Breakdown of cash position:
• Income tax refund from ATO of A$3.6m (recently announced)
• Estimated R&D rebate of A$7.5 million from the ATO in 2026
• Non-dilutive capital anticipated in 2026 through R&D advance ($A10 million)
• Pro-forma cash position of A$33.1 million post capital raising
Recce Pro-forma Cash Position
$-
$0.10
$0.20
$0.30
$0.40
$0.50
$0.60
$0.70
$0.80
-
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1,400,000
1,600,000
Summary
15
Recce is approaching a number of near term significant value creating opportunities with commercialisation
Novel, Synthetic, Broad-Spectrum,
Rapid-Acting, Anti-Infectives:
demonstrated against >500 clinical
isolates including all resistant species;
no signs of resistance to R327
Approaching pivotal clinical and
commercial inflection point with
interim data read out for Indonesian
Phase 3 registrational clinical trial
expected commercialisation 2027
Upon completion of Phase 3
registrational clinical trial, enables
Recce to commence
commercialisation across ASEAN
and MENA region
Non-binding term sheet with leading
Middle Eastern pharmaceutical
company to support commercial sales
and distribution capability through
MENA region
Development of a first new class of
antibiotic in over 40 years, recognised
by the World Health Organization, with
accelerated de-risking via registrational
Phase 3 trials in Indonesia and Australia
recce.com.au
Thank you
Share your feedback
Discover